RhumbLine Advisers
RLMD icon

RhumbLine Advisers’s Relmada Therapeutics RLMD Stock Holding History

RhumbLine Advisers’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$817K Buy
+118,108
New +$825K ﹤0.01% 2449
2024
Q3 		– Sell
-1,125
Closed -$3.38K – 4310
2024
Q2 		$3.38K Sell
1,125
-49
-4% -$177 ﹤0.01% 4140
2024
Q1 		$5.46K Hold
1,174
– – ﹤0.01% 3972
2023
Q4 		$4.86K Hold
1,174
– – ﹤0.01% 3988
2023
Q3 		$3.52K Sell
1,174
-2,274
-66% -$6.75K ﹤0.01% 4037
2023
Q2 		$8.48K Sell
3,448
-34,187
-91% -$94.5K ﹤0.01% 3984
2023
Q1 		$85K Buy
37,635
+1,092
+3% +$3.77K ﹤0.01% 2876
2022
Q4 		$128K Buy
36,543
+280
+0.8% +$2.46K ﹤0.01% 2871
2022
Q3 		$1.34M Buy
36,263
+2,828
+8% +$78.3K ﹤0.01% 1986
2022
Q2 		$635K Buy
33,435
+11,876
+55% +$259K ﹤0.01% 2365
2022
Q1 		$582K Buy
21,559
+5,975
+38% +$124K ﹤0.01% 2354
2021
Q4 		$351K Sell
15,584
-242
-2% -$5.38K ﹤0.01% 2658
2021
Q3 		$415K Buy
15,826
+673
+4% +$18K ﹤0.01% 2630
2021
Q2 		$485K Sell
15,153
-1,240
-8% -$43.1K ﹤0.01% 2579
2021
Q1 		$577K Sell
16,393
-735
-4% -$25.7K ﹤0.01% 2420
2020
Q4 		$549K Buy
17,128
+1,130
+7% +$38.8K ﹤0.01% 2403
2020
Q3 		$602K Sell
15,998
-1,845
-10% -$71.3K ﹤0.01% 2198
2020
Q2 		$798K Buy
+17,843
New +$754K ﹤0.01% 2136

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

RhumbLine Advisers's RLMD Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 118,108 shares worth $817K. The stake represents ﹤0.01% of the portfolio and ranks #2449 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in RLMD as recently as Q2 2024.

RhumbLine Advisers first reported a position in RLMD in Q2 2020 and has held it in 18 quarters since. The position peaked at $1.34M in Q3 2022. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • RhumbLine Advisers held 118,108 shares of Relmada Therapeutics worth $817K as of Q2 2026.
  • Relmada Therapeutics was a new RhumbLine Advisers position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2449 holding.
  • RhumbLine Advisers first reported a position in Relmada Therapeutics in Q2 2020 and has held it in 18 quarters since.
  • RhumbLine Advisers's Relmada Therapeutics position peaked at $1.34M in Q3 2022.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.